Category Research

Celltrion Highlights Two-Year Analysis Supporting Dose Escalation for CT-P13 SC in IBD

Celltrion has announced two-year findings from a post-hoc analysis of the LIBERTY studies (LIBERTY-CD and LIBERTY-UC), presented at United European Gastroenterology (UEG) Week 2024 in Vienna. The analysis shows that dose escalation of subcutaneous infliximab (CT-P13 SC) is effective for…

Read MoreCelltrion Highlights Two-Year Analysis Supporting Dose Escalation for CT-P13 SC in IBD

Merck’s Clesrovimab Significantly Reduces RSV Incidence and Hospitalizations in Infants

Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has shared positive results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, an investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) during their first…

Read MoreMerck’s Clesrovimab Significantly Reduces RSV Incidence and Hospitalizations in Infants

ClearB Therapeutics Partners With Adjuvance for Saponin Adjuvant, to Present Hepatitis B Data at AASLD 2024

ClearB Therapeutics Licenses Novel Saponin Adjuvant TQL-1055, to Present Hepatitis B Vaccine Data at AASLD 2024 ClearB Therapeutics, a company focused on developing therapeutic vaccines for a functional cure of Hepatitis B, has licensed the novel saponin-based adjuvant TQL-1055 from…

Read MoreClearB Therapeutics Partners With Adjuvance for Saponin Adjuvant, to Present Hepatitis B Data at AASLD 2024

DIA Canada Annual Meeting to Focus on Precision Regulation and Clinical Trial Advancements

Life Sciences Experts to Explore Global Collaboration, AI, and Clinical Trial Innovation at DIA Canada Annual Meeting The upcoming DIA Canada Annual Meeting, taking place on November 14-15 in Gatineau, Quebec, will gather life sciences leaders to discuss Canada’s precision…

Read MoreDIA Canada Annual Meeting to Focus on Precision Regulation and Clinical Trial Advancements

Clarametyx Biosciences Reports Advancements in CMTX-101 Antibody Therapy for Cystic Fibrosis Infections

Clarametyx Biosciences Moves Forward with Phase 2a Study of CMTX-101 for Cystic Fibrosis Infections Clarametyx Biosciences, Inc. has successfully completed the Phase 1b portion of its clinical trial for CMTX-101, a novel immune-enabling antibody therapy aimed at treating pulmonary infections…

Read MoreClarametyx Biosciences Reports Advancements in CMTX-101 Antibody Therapy for Cystic Fibrosis Infections

Kezar Life Sciences Shares Positive PORTOLA Trial Safety Review for Zetomipzomib

Kezar Life Sciences Updates on Clinical Trials for Zetomipzomib Kezar Life Sciences, Inc. (Nasdaq: KZR), a biotechnology company focused on developing innovative therapeutics for immune-mediated diseases, has provided important updates on its clinical trials. The Independent Data Monitoring Committee (IDMC)…

Read MoreKezar Life Sciences Shares Positive PORTOLA Trial Safety Review for Zetomipzomib

Marinus Pharma Shares Phase 3 RAISE Trial Results on Refractory Status Epilepticus at Neurocritical Care 2024

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative therapies for seizure disorders, has shared new data from its Phase 3 RAISE trial on intravenous (IV) ganaxolone for refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS)…

Read MoreMarinus Pharma Shares Phase 3 RAISE Trial Results on Refractory Status Epilepticus at Neurocritical Care 2024

Shionogi Showcases Global Study on Cefiderocol Highlighting High Clinical Response in Critically Ill Patients

Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for treating seriously ill adult patients with Gram-negative (GN) bacterial infections.…

Read MoreShionogi Showcases Global Study on Cefiderocol Highlighting High Clinical Response in Critically Ill Patients